DC
ALNY icon

Davenport & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Davenport & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Sell
1,802
-40
-2% -$12.1K ﹤0.01% 978
2026
Q1 		$609K Buy
1,842
+83
+5% +$28.2K ﹤0.01% 859
2025
Q4 		$699K Buy
+1,759
New +$778K ﹤0.01% 801
2022
Q1 		– Sell
-3,705
Closed -$628K – 1062
2021
Q4 		$628K Buy
3,705
+288
+8% +$53.5K ﹤0.01% 695
2021
Q3 		$645K Buy
3,417
+533
+18% +$100K ﹤0.01% 659
2021
Q2 		$489K Buy
+2,884
New +$422K ﹤0.01% 650

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
PSC
Portman Square Capital London, United Kingdom $2.11B AUM 19.71% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return

Davenport & Co's ALNY Position: Q2 2026 in Review

Davenport & Co reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.2% in Q2 2026, selling an estimated $12.1K and leaving 1,802 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Davenport & Co first reported a position in ALNY in Q2 2021 and has held it in 6 quarters since. The position peaked at $699K in Q4 2025. 96 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Davenport & Co held 1,802 shares of Alnylam Pharmaceuticals worth $542K as of Q2 2026.
  • Davenport & Co sold 40 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #978 holding.
  • Davenport & Co first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 6 quarters since.
  • Davenport & Co's Alnylam Pharmaceuticals position peaked at $699K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.